MXPA03002389A - Un metodo de analgesica. - Google Patents

Un metodo de analgesica.

Info

Publication number
MXPA03002389A
MXPA03002389A MXPA03002389A MXPA03002389A MXPA03002389A MX PA03002389 A MXPA03002389 A MX PA03002389A MX PA03002389 A MXPA03002389 A MX PA03002389A MX PA03002389 A MXPA03002389 A MX PA03002389A MX PA03002389 A MXPA03002389 A MX PA03002389A
Authority
MX
Mexico
Prior art keywords
pain
analgesia
alleviate
essentially
composition
Prior art date
Application number
MXPA03002389A
Other languages
English (en)
Inventor
Qingbin Dong
Original Assignee
Wex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wex Medical Ltd filed Critical Wex Medical Ltd
Publication of MXPA03002389A publication Critical patent/MXPA03002389A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Laser Surgery Devices (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

Esta invencion se relaciona con un metodo de produccion analgesica en el mamifero experimentando dolor mediante la administracion sistemica de una concentracion efectiva de una composicion constituido esencialmente de un compuesto bloqueador del canal de sodio, en un diluyente farmaceutico adecuado, para aliviar el dolor.
MXPA03002389A 2000-09-18 2001-09-11 Un metodo de analgesica. MXPA03002389A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
PCT/CN2001/001391 WO2002022129A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Publications (1)

Publication Number Publication Date
MXPA03002389A true MXPA03002389A (es) 2004-03-12

Family

ID=4590472

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002389A MXPA03002389A (es) 2000-09-18 2001-09-11 Un metodo de analgesica.

Country Status (26)

Country Link
US (1) US6407088B1 (es)
EP (3) EP2298306B1 (es)
JP (1) JP2004508404A (es)
KR (2) KR100891568B1 (es)
CN (1) CN1284536C (es)
AT (2) ATE447959T1 (es)
AU (1) AU2002213785A1 (es)
BG (1) BG107690A (es)
BR (1) BR0113961A (es)
CA (1) CA2421562C (es)
DE (1) DE60140466D1 (es)
EA (1) EA004870B1 (es)
EE (1) EE200300106A (es)
ES (1) ES2435463T3 (es)
HR (1) HRP20030202A2 (es)
HU (1) HUP0302677A3 (es)
IL (1) IL154342A0 (es)
IS (1) IS6719A (es)
MX (1) MXPA03002389A (es)
NO (1) NO323960B1 (es)
PL (1) PL360616A1 (es)
SK (1) SK3732003A3 (es)
UA (1) UA76960C2 (es)
WO (1) WO2002022129A1 (es)
YU (1) YU17103A (es)
ZA (1) ZA200301852B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047869A1 (en) 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
US20030100574A1 (en) 2001-11-15 2003-05-29 Wilson Nestor Antonio Lagos Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
AU2003250128A1 (en) * 2002-08-01 2004-02-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
CA2607206C (en) * 2004-05-07 2016-06-14 Phytotox Limited Transdermal administration of phycotoxins
EP1824488B1 (en) * 2004-05-07 2017-08-09 Algenis SpA Phycotoxins and uses thereof
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
EP1799219A1 (en) * 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
US20100075992A1 (en) * 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
EP1714655A1 (en) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
TW200640463A (en) * 2005-02-11 2006-12-01 Esteve Labor Dr Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1690541A1 (en) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
EP1928452A4 (en) * 2005-08-25 2010-09-01 Wex Medical Ltd USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
EP1931349A4 (en) * 2005-08-25 2009-08-05 Wex Pharmaceuticals Inc USE OF SODIUM CHANNEL BLOCKERS TO TREAT MUSCULO-SKELETAL PAIN
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (en) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of preterm labor
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
EP1844783A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel - subunit Nav1.6
WO2007110221A1 (en) 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
EP1844782A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (en) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain
EP2173167A4 (en) * 2007-07-06 2010-07-28 Nuon Therapeutics Inc TREATMENT OF NEUROPATHIC PAIN
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
WO2010117996A1 (en) * 2009-04-08 2010-10-14 Children's Medical Center Corporation Prolonged duration local anesthesia with minimal toxicity
EP2533785B1 (en) * 2010-02-10 2014-04-23 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
JP2014504184A (ja) 2010-12-01 2014-02-20 スパイナル・モデュレーション・インコーポレイテッド 神経構造への薬剤の直接送達
CN105189553A (zh) 2013-03-14 2015-12-23 瑞泽恩制药公司 Nav1.7的人抗体
JP6313420B2 (ja) 2013-03-15 2018-04-18 ザ チルドレンズ メディカル センター コーポレイション 持続する局所麻酔のためのネオサキシトキシン併用製剤
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
AU6883798A (en) * 1997-04-02 1998-10-22 Regents Of The University Of California, The Method of anesthesia
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
JP2004508404A (ja) 2004-03-18
NO20030915L (no) 2003-04-25
KR100891568B1 (ko) 2009-04-03
CN1356104A (zh) 2002-07-03
EE200300106A (et) 2005-04-15
HUP0302677A3 (en) 2005-01-28
CA2421562A1 (en) 2002-03-21
SK3732003A3 (sk) 2005-05-05
EP1563839B1 (en) 2012-01-25
IS6719A (is) 2003-02-14
EP1320369A1 (en) 2003-06-25
ES2435463T3 (es) 2013-12-19
EP2298306B1 (en) 2013-09-11
EA004870B1 (ru) 2004-08-26
PL360616A1 (en) 2004-09-20
CN1284536C (zh) 2006-11-15
ATE447959T1 (de) 2009-11-15
ZA200301852B (en) 2004-06-21
EP2298306A1 (en) 2011-03-23
KR20030034181A (ko) 2003-05-01
EA200300172A1 (ru) 2003-12-25
AU2002213785A1 (en) 2002-03-26
NO323960B1 (no) 2007-07-23
UA76960C2 (en) 2006-10-16
DE60140466D1 (de) 2009-12-24
ATE542534T1 (de) 2012-02-15
WO2002022129A1 (en) 2002-03-21
BG107690A (bg) 2004-01-30
EP1320369A4 (en) 2003-07-02
EP1320369B1 (en) 2009-11-11
EP1563839A1 (en) 2005-08-17
IL154342A0 (en) 2003-09-17
KR20070112864A (ko) 2007-11-27
CA2421562C (en) 2011-05-24
YU17103A (sh) 2006-03-03
BR0113961A (pt) 2004-01-13
HRP20030202A2 (en) 2005-02-28
HUP0302677A2 (hu) 2003-11-28
US6407088B1 (en) 2002-06-18
NO20030915D0 (no) 2003-02-27

Similar Documents

Publication Publication Date Title
YU17103A (sh) Metod analgezije
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
DE60329001D1 (en) 8-hydroxychinolinderivate
AU3652102A (en) Compounds and their uses
IL142864A0 (en) Compositions and methods for producing vascular occlusion
ZA200606173B (en) Effervescent oral opiate dosage form
GB0122318D0 (en) Organic compounds
WO1999015159A3 (en) Methods for increasing apoe levels for the treatment of neurodegenerative disease
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
MXPA03007678A (es) Composicion farmaceutica oral de proxetil cefpodoxima.
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
MXPA03005601A (es) Nuevos compuestos y composiciones como inhibidores de catepsina.
DE59800935D1 (en) Immuntolerante prothrombinkomplex-präparation
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
BG105197A (en) Polymorph form of a medicament
WO2002062322A3 (en) Glycine betaine and its use as anti-hemorrhagic agent
GB2358137B (en) Compound
NZ523606A (en) Pharmaceutical compositions and methods for use
AU4445201A (en) Method for administering insulin to the buccal region
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
UA83011C2 (ru) Соединения для лечения табачной зависимости и синдрома отмены
WO2005058363A3 (en) Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor
AU5434899A (en) Cancer treatment
MY136719A (en) Surfactant system for increasing dental tissue antibacterial agent uptake
WO2005020982A3 (en) Using selective antagonists of persistent sodium current to treat neurological disorders and pain

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration